MICHAEL SCOTT VISSER,JULIEN PAPILLON,MICHAEL JOSEPH LUZZIO
申请号：
CL2017000290
公开号：
CL2017000290A1
申请日:
2017.02.03
申请国别(地区):
CL
年份:
2017
代理人:
摘要：
<； p >； are inhibitors of PKC. The inhibitors of PKC are Brand； useful for the treatment of diseases associated with PKC, including some types of C & aacute； cancer.The inhibitors of PKC have improved Efficiency in dose amounts M & aacute； s low to achieve regression of tumor Bertalanffy, Improved power Absorption, PK Profile, Bertalanffy, gastrointestinal tolerance and selectivity of Kinase. <； / p >；Compuestos derivados de 3-amino-6-piridin-2-il o 1,3-pirimidin-4-il-N-3-piperidin-1-il-piridin-2-il-pirazina-2-carboxamida, inhibidores de la proteína quinasa C composiciones farmacológicas útiles para el tratamiento de trastornos autoinmunes, reacciones alérgicas y rechazo de trasplantes de tejidos, cáncer tal como melanoma, linfoma, entre otros.
